ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis
Authors
Alberto Mendoza‐Ticona (ORCID: https://orcid.org/0000-0002-2571-2894)
Radojka M. Savić (ORCID: https://orcid.org/0000-0003-3143-5579)
Rebecca G. Rogers (ORCID: https://orcid.org/0000-0002-3991-7348)
Kelly E. Dooley (ORCID: https://orcid.org/0000-0001-9013-5256)
William Murtaugh
Colleen Foley
Marjorie Z. Imperial (ORCID: https://orcid.org/0000-0001-7434-3012)
Patrick P. J. Phillips (ORCID: https://orcid.org/0000-0002-6336-7024)
Shawn Chiambah
Jennifer Furin (ORCID: https://orcid.org/0000-0002-0825-7199)
Eunsol Yang (ORCID: https://orcid.org/0000-0003-2581-349X)
National Institute of Allergy and Infectious Diseases
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis
Alberto Mendoza‐Ticona, Radojka M. Savić, Rebecca G. Rogers, Kelly E. Dooley et al.
Citations
2 citations
Journal
Trials
Topics
Tuberculosis Research and Epidemiology
Field-Weighted Citation Impact (FWCI)
2.79
article
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis
Alberto Mendoza‐Ticona, Radojka M. Savić, Rebecca G. Rogers, Kelly E. Dooley, William Murtaugh, Colleen Foley, Marjorie Z. Imperial, Patrick P. J. Phillips, Shawn Chiambah, Jennifer Furin, Eunsol Yang, Justin Shenje, Salah Foraida, Russell Ryan Kempker, Rachel Kyeyune, Eric L. Nuermberger, Janeway Granche, Sandy Nerette, Gustavo E. Velásquez, Melanie Goth, Cecilia Kanyama, Andrew Vernon, Jhoanna Roa, Elisa H. Ignatius, Linda J. Harrison, Susan E. Dorman, Austin Van Grack
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
TrialsVol. 26(1)
Institutions
Johns Hopkins University (US), Emory University (US), Medical University of South Carolina (US), University of California, San Francisco (US), UCLA Health (US), TB Alliance (US), Cancer Research And Biostatistics (US), Social and Scientific Systems (United States) (US), South African Tuberculosis Vaccine Initiative (ZA), EsSALUD (PE), National Institute of Allergy and Infectious Diseases (US), Gheskio Centers (HT), Frontier Science & Technology Research Foundation, Inc. (US), Case Western Reserve University (US), Vanderbilt University Medical Center (US)
Funders
ACT Government, National Institutes of Health, National Institute of Allergy and Infectious Diseases